BGB-11417-101: what clinicians are saying
sonrotoclax; sonrotoclax plus zanubrutinib; sonrotoclax plus zanubrutinib plus obinutuzumab in mature B-cell malignancies · NCT04277637 ↗ · Phase 1 · BeOne Medicines
A hematologist described in the sources as reporting their own results reads BGB-11417-101 favorably for its MRD clearance, but remains uncertain about PFS translation. A speaker described as presenting and authoring the results envisages displacing ibrutinib–venetoclax on tolerability grounds; another speaker described as presenting the trial emphasizes response depth. These predictions lack a direct comparison between combinations. Longer follow-up and randomized confirmation are still awaited.
Created with AI · how we check it
- edition 1
- commentary checked Nov 20, 2026
- 133 verified statements
This edition $750, with MCP access for your AI agent. Get this report
13 findings, and what sits behind each
01. CLL MRD depth: what speakers highlight without settling its clinical meaning
1 of the report's 6 cited clinicians · 11 statements from 2 speakers in 4 sources, all podcasts or videos · 6 passages
Limitations recorded: 2.
Draws on: The comparison, Design and conduct, Safety and tolerability.
02. CLL doublets: why some speakers foresee possible replacement of ibrutinib–venetoclax
2 of the report's 6 cited clinicians · 18 statements from 4 speakers in 9 sources, all podcasts or videos · 12 passages
Limitations recorded: 3.
Draws on: The comparison, Secondary endpoints, Safety and tolerability, Population and setting.
03. CLL: a speaker favors finite therapy but retains a continuous BTKi option
No named clinician · accounts and unnamed speakers · 6 statements from 1 speaker in 1 source, a podcast or video · 3 passages
Limitations recorded: 3.
Draws on: Population and setting, The comparison, Design and conduct.
04. CLL doublet: how most speakers weigh tolerability against neutropenia and infections
2 of the report's 6 cited clinicians · 15 statements from 3 speakers in 9 sources, 7 of them podcasts or videos · 12 passages
Limitations recorded: 3.
Draws on: Safety and tolerability, Primary endpoint: Number of Participants Experiencing Treatment Emergent Adverse Events (TEAEs), Primary endpoint: Part 1, Part 3, Part 5: Number of participants experiencing tumor lysis syndrome (TLS) relevant events, Population and setting, Primary endpoint: Number of Participants Experiencing Adverse Events (AEs) leading to discontinuation of Sonrotoclax, Primary endpoint: Part 1, Part 3, Part 5: RP2D of Sonrotoclax.
05. 320-mg sonrotoclax: why a speaker sees an efficacy–tolerability balance, not an MTD
1 of the report's 6 cited clinicians · 5 statements from 2 speakers in 4 sources, all podcasts or videos · 5 passages
Limitations recorded: 2.
Draws on: Primary endpoint: Part 1, Part 3: Maximum Tolerated Dose (MTD) of Sonrotoclax, Primary endpoint: Part 1, Part 3, Part 5: RP2D of Sonrotoclax, Design and conduct, Primary endpoint: Part 1, Part 3, Part 5: Number of Participants Experiencing Dose-Limiting Toxicities (DLTs.
06. Ramp-up: a speaker eyes shortening after study; a clinician values outpatient use
1 of the report's 6 cited clinicians · 9 statements from 3 speakers in 7 sources, all podcasts or videos · 9 passages
Limitations recorded: 3.
Draws on: Primary endpoint: Part 1, Part 3, Part 5: Number of participants experiencing tumor lysis syndrome (TLS) relevant events, Safety and tolerability, Secondary endpoints, Design and conduct, Primary endpoint: Number of Participants Experiencing Treatment Emergent Adverse Events (TEAEs), Population and setting.
07. R/R CLL: a clinician highlights MRD depth but leaves time off treatment unspecified
1 of the report's 6 cited clinicians · 16 statements from 1 speaker in 2 sources, all podcasts or videos · 4 passages
Limitations recorded: 3.
Draws on: Safety and tolerability, Primary endpoint: Number of Participants Experiencing Treatment Emergent Adverse Events (TEAEs), Population and setting, Design and conduct, Primary endpoint: Part 1, Part 3: Maximum Tolerated Dose (MTD) of Sonrotoclax, Primary endpoint: Part 1, Part 3, Part 5: RP2D of Sonrotoclax, Primary endpoint: Part 1, Part 3, Part 5: Number of participants experiencing tumor lysis syndrome (TLS) relevant events, The comparison.
08. First-line CLL: what speakers highlight in response rates and uMRD
1 of the report's 6 cited clinicians · 16 statements from 3 speakers in 5 sources, 2 of them podcasts or videos · 8 passages
Limitations recorded: 2.
Draws on: The comparison, Primary endpoint: Part 1, Part 3, Part 5: Number of participants experiencing tumor lysis syndrome (TLS) relevant events, Safety and tolerability, Population and setting.
09. Sonrotoclax–obinutuzumab: a clinician sees MRD-led stops; one awaits an RCT
2 of the report's 6 cited clinicians · 8 statements from 2 speakers in 2 sources, 1 of them a podcast or video · 2 passages
Limitations recorded: 3.
Draws on: Primary endpoint: Number of Participants Experiencing Treatment Emergent Adverse Events (TEAEs), Primary endpoint: Number of Participants Experiencing Adverse Events (AEs) leading to discontinuation of Sonrotoclax, Primary endpoint: Part 1, Part 3, Part 5: Number of participants experiencing tumor lysis syndrome (TLS) relevant events, The comparison, Safety and tolerability, Design and conduct.
10. CLL triplet: what a clinician highlights in early off-treatment remission
1 of the report's 6 cited clinicians · 12 statements from 1 speaker in 1 source, a podcast or video · 3 passages
Limitations recorded: 4.
Draws on: Design and conduct, Population and setting, The comparison, Safety and tolerability, Primary endpoint: Number of Participants Experiencing Treatment Emergent Adverse Events (TEAEs), Primary endpoint: Part 1, Part 3, Part 5: Number of participants experiencing tumor lysis syndrome (TLS) relevant events, Primary endpoint: Number of Participants Experiencing Adverse Events (AEs) leading to discontinuation of Sonrotoclax, Primary endpoint: Part 1, Part 3, Part 5: RP2D of Sonrotoclax, Secondary endpoints.
11. Sonrotoclax in MCL: where speakers split on how far early findings go
1 of the report's 6 cited clinicians · 6 statements from 2 speakers in 4 sources, 2 of them podcasts or videos · 4 passages
Limitations recorded: 3.
Draws on: Safety and tolerability, Population and setting.
12. Sonrotoclax in WM: why most speakers see phase 1 as grounds for further study
2 of the report's 6 cited clinicians · 9 statements from 3 speakers in 3 sources, 2 of them podcasts or videos · 3 passages
Limitations recorded: 3.
Draws on: Primary endpoint: Number of Participants Experiencing Treatment Emergent Adverse Events (TEAEs), Primary endpoint: Number of Participants Experiencing Adverse Events (AEs) leading to discontinuation of Sonrotoclax, Primary endpoint: Part 1, Part 3, Part 5: Number of participants experiencing tumor lysis syndrome (TLS) relevant events, Population and setting, The comparison, Safety and tolerability.
13. Phase 1 sonrotoclax: a clinician tempers DLBCL hopes but favors CLL combination study
1 of the report's 6 cited clinicians · 11 statements from 2 speakers in 4 sources, all podcasts or videos · 6 passages
Limitations recorded: 2.
Draws on: Safety and tolerability, Primary endpoint: Number of Participants Experiencing Treatment Emergent Adverse Events (TEAEs), The comparison, Design and conduct, Primary endpoint: Part 1, Part 3, Part 5: RP2D of Sonrotoclax, Primary endpoint: Part 1, Part 3, Part 5: Number of participants experiencing tumor lysis syndrome (TLS) relevant events, Population and setting.
Counts overlap, since one statement can back several findings. They show what the report kept, not how many clinicians agree. The full report includes the interpretations and source links.
Select a finding to see what the full report holds for it. Select a part of the trial to see which findings draw on it.
- Finding 1 of 13
1 of the report's 6 cited clinicians
CLL MRD depth: what speakers highlight without settling its clinical meaning
11 statements from 2 speakers in 4 sources, all podcasts or videos
2 of the 2 named speakers in this finding hold this view; 2 of them hold its caveat, “without settling its clinical meaning”
- 11
- statements
- 6
- passages
- 4
- sources
- 2
- speakers
What the statements areViews 7Questions and uncertainty 2Clinical experience 0Comparisons 1Restated results and context 1Statement-to-passage links (a passage can back several statements)Supporting a statement 11Giving context 2Recorded with the findingLimitations: 2
4 podcasts and video
Draws on: The comparison, Design and conduct, Safety and tolerability.
Thicker lines mean more shared statements. A finding without a line goes beyond the registered design. Counts overlap: one statement can back several findings.
Abbreviations (11)
AE, adverse event; DLT, dose-limiting toxicity; HCP, healthcare professional; MCP, Model Context Protocol, how AI agents read the report; MRD, measurable residual disease; MTD, maximum tolerated dose; NPI, National Provider Identifier, the US registry number for clinicians; PFS, progression-free survival; RCT, randomized controlled trial; RP2D, recommended phase 2 dose; SAE, serious adverse event.
The full BGB-11417-101 report gives each finding its interpretation, the attributed views behind it, counterviews, limits and the verified statements, each linked to the original. One report in the catalog, IDeate-Lung01, is free in full, so you can see what a paid report holds before you buy: read the free IDeate-Lung01 report.
What do clinicians say they need to see from longer follow-up of sonrotoclax plus zanubrutinib in CLL to determine whether undetectable MRD translates into prolonged PFS?
From finding F1 (11 statements from 2 speakers in 4 sources). The report shows what clinicians said and the sources behind it; it does not settle the question.
By the numbers
- 55commentary sources screened
- 27sources cited by verified statements
- 11named in screened sources
- 11speakers cited in the report
- 9cited speakers with a verified identity
6 cited clinicians, speakers with a confirmed clinical role, of them 6 physicians. By role and specialty:
- 3 physician, specialty not confirmed
- 2 physician, Medical oncology
- 1 physician, Hematology
Also in the sources: 1 organizational or shared account, not counted as people.
- 133verified statements, each linked to its source
- 68of them from speakers with a confirmed clinical role
- 13findings
Built by AI from public clinician commentary, checked by automated review; every statement links to its source.
A cited clinician is a cited speaker whose clinical role the NPI registry or their own institution's staff page confirms; a role a source only states is not counted. A verified identity says who a speaker is, with or without such a role. Physicians are clinicians whose confirmed role is a physician's.
Counts show what the report kept, not how many clinicians hold a view. Size is set by the verified statements; Standard and Deep need 5 or more cited clinicians. Statements from sponsors, hosts and organisations are labelled and count apart.
What's inside
| Section | Items | Access |
|---|---|---|
| Findings with interpretation, counterviews and limits | 13 | Titles free |
| Detailed analysis | 14 sections | Paid |
| Verified statements with short source quotes and links | 133 | Paid |
| Who said each statement: the cited speakers | 11 | Every edition |
| Speakers with a clinical role confirmed by the NPI registry or a staff page | 6 | Every edition |
| Speakers with verified IDs as data (NPI, ORCID, staff page) | 9 | Every edition |
| CMS-reported financial relationships (Open Payments, by company) for NPI-linked speakers | Included | Every edition |
| Trial aspects mapped | 17 | Free |
| Sources with links | 27 | Counts free |
| MCP access for your AI agent, same license key | Included | Every edition |
Every edition names who said each statement, with MCP access for your AI agent. Each verified speaker comes with their verified IDs (NPI, ORCID, staff page) so your team can check each attribution. Allowed: advisory boards, scientific exchange and finding investigators, under your own compliance process. Not allowed: sales or marketing to clinicians.
Trial aspects
16 discussed · 1 no commentary found · 0 assessment incomplete| Aspect | Statements | Sources |
|---|---|---|
| Primary endpoint: Number of Participants Experiencing Treatment Emergent Adverse Events (TEAEs) | 19 | 12 |
| Primary endpoint: Number of Participants Experiencing Serious Adverse Events (SAEs)no commentary found | 0 | 0 |
| Primary endpoint: Number of Participants Experiencing Adverse Events (AEs) leading to discontinuation of Sonrotoclax | 6 | 5 |
| Primary endpoint: Part 1, Part 3: Maximum Tolerated Dose (MTD) of Sonrotoclax | 3 | 3 |
| Primary endpoint: Part 1, Part 3, Part 5: RP2D of Sonrotoclax | 5 | 5 |
| Primary endpoint: Part 1, Part 3, Part 5: Number of participants experiencing tumor lysis syndrome (TLS) relevant events | 15 | 11 |
| Primary endpoint: Part 1, Part 3, Part 5: Number of Participants Experiencing Dose-Limiting Toxicities (DLTs | 2 | 2 |
| Secondary endpoints | 4 | 4 |
| Population and setting | 16 | 10 |
| The comparisonThe registered arms and what clinicians said about how they compare. | 26 | 16 |
| Safety and tolerability | 30 | 16 |
| Design and conduct | 19 | 8 |
| How speakers interpret MRD depth, response and durability | 36 | 16 |
| Finite therapy, continuous BTK inhibition and patient burden | 14 | 5 |
| Pharmacologic differentiation, resistance hypotheses and escalation opportunities | 21 | 14 |
| Histology-specific activity and reasons for further development | 19 | 10 |
| Research enrollment, validation needs and strength of endorsement | 25 | 21 |
Discussed means at least one verified statement addresses the aspect, not that every question in it is covered: gaps inside a discussed aspect are listed under Scope and limits, and the full report gives each aspect its own limitations. No commentary found means none in the sources read. Assessment incomplete marks an aspect with no statement found while known source limits apply.
Sources
133 verified statements from 27 cited sources. A video or podcast is one source but often carries many statements, so the table counts statements, not just posts.
| Channel | Statements | Cited | Screened | |
|---|---|---|---|---|
| Video & audio · 119 statements · 89% | ||||
| YouTube | 94 | 17 | 18 | |
| X videos | 1 | 1 | 1 | |
| Podcasts | 24 | 2 | 2 | |
| Posts · 14 statements · 11% | ||||
| X threads | 9 | 6 | 31 | |
| Bluesky threads | 5 | 1 | 3 | |
Screened: found and read for this trial. Cited: backs at least one statement. Bar = statements; a statement drawn from two sources counts half to each. How we sourced and checked this
max 7 / quarter
- Screened window
- Apr 14, 2021 → Nov 11, 2026
- Cited window
- Jun 11, 2021 → Jul 21, 2026
- Retrieved
- Nov 19, 2026
The trial
from ClinicalTrials.gov- Title
- A Phase 1a/1b Open-Label Dose Escalation and Expansion Study of Bcl-2 Inhibitor BGB-11417 in Patients With Mature B-Cell Malignancies
- Registry
- NCT04277637
- Study IDs
- BGB-11417-101 · 2024-515592-35-00 · 2020-004641-37
- Sponsor
- BeOne Medicines
- Design
- Phase 1 · Interventional, non randomized, parallel
- Status
- Active, not recruiting
- Enrollment
- 437 actual
- Registered
- 2020-02-20
- Start
- 2020-03-24 actual
- Primary completion
- 2027-05-31 estimated
- Primary endpoints
- Number of Participants Experiencing Treatment Emergent Adverse Events (TEAEs)
- Number of Participants Experiencing Serious Adverse Events (SAEs)
- Number of Participants Experiencing Adverse Events (AEs) leading to discontinuation of Sonrotoclax
- Part 1, Part 3: Maximum Tolerated Dose (MTD) of Sonrotoclax
- Part 1, Part 3, Part 5: RP2D of Sonrotoclax
- Part 1, Part 3, Part 5: Number of participants experiencing tumor lysis syndrome (TLS) relevant events
- Part 1, Part 3, Part 5: Number of Participants Experiencing Dose-Limiting Toxicities (DLTs
- Interventions
- 3 registered
More on: Mature B-cell malignancies, sonrotoclax, zanubrutinib, obinutuzumab
Scope and limits
This report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.
- Discussion that does not name the trial may be missing from this edition.
- For 1 recording, a transcript separated by speaker was not available, so quotes come from the original automatic transcript and may lack speaker labels.
- 1 cited commentary passage leaves a source question open, such as who was speaking. The report attributes no further than the source shows.
- Not yet captured in this edition: a view on the efficacy and tolerability of frontline sonrotoclax plus zanubrutinib in CLL; a remark on early-phase safety and activity in Waldenström macroglobulinemia, including prior BTK inhibitor exposure; a remark on speaker attribution and the relayed nature of first-line sonrotoclax–zanubrutinib commentary; a view on fixed-duration frontline CLL treatment alternatives and their long-term efficacy and safety considerations.
- 2 passages in 2 sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.
Show all 15 known gaps +Fewer −
- 47 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.
- Further source limits: 21 sources about other trials or topics are not included.
- The sources reviewed for this edition are selected public discussions rather than a representative survey of HCP practice or opinion.
- Several speakers are described by their sources as presenting, authoring or reporting the trial. Those descriptions are attributed source information, not independent confirmation of involvement or an external endorsement.
- Repeated posts, reposts, interviews and reused excerpts should not be counted as independent HCP endorsements.
- Some remarks remain unnamed even when a source title, introduction or participant list names a possible speaker. Those remarks cannot establish ownership of a named view.
- No protocol or exact-trial results publication was available among the sources reviewed, limiting checks of cohort definitions, denominators and event attribution.
- Different updates use different settings, dose cohorts, MRD thresholds, evaluable populations and follow-up. Their percentages and no-event statements should not be pooled.
- Unclear deletion labels and inconsistent recalled timing are left unresolved. They are not corrected to a presumed clinical meaning.
- No separate assessment or count of serious adverse events was found in the commentary presented here; high-grade toxicity statements cannot substitute for that endpoint.
How reports are built and checked: Methods.
Editions and corrections
Last checked for new commentary Nov 20, 2026 UTC. No changes. Follow new editions and changes in this report's change feed (JSON Feed), or the catalog's. How versions and corrections work.
Cite this report
Erudio Health. BGB-11417-101 (NCT04277637): HCP commentary report. Edition 1, v1.0.0. Accepted Nov 20, 2026. https://www.erudio.com/reports/bgb-11417-101-nct04277637
For your AI agent
Paste this into ChatGPT, Claude, Microsoft Copilot or your own agent. It previews this report through the free Erudio MCP server, tells you whether it answers your question, and orders it if you ask. Some agents ask you to confirm pasted instructions before acting; that is expected.
Help me decide whether to buy the Erudio report "BGB-11417-101" (NCT04277637), and buy it for me if I ask. Erudio reports cover what clinicians say in public about one clinical trial, with every verified statement linked to its source.
1. Use the free Erudio MCP server at https://mcp.erudio.com/free; it needs no sign-in. Nothing needs installing: if it is not connected in this app and you can make HTTP requests, call it directly with JSON-RPC POSTs to that URL (initialize, then tools/call), sending "Accept: application/json, text/event-stream". Call get_report_card with slug "bgb-11417-101-nct04277637". If you cannot make requests, read https://www.erudio.com/reports/bgb-11417-101-nct04277637.md instead.
2. In a few lines, tell me what the report covers: its findings, its verified statements and sources, its evidence window, what it leaves out, and the price of each product (offer). Then ask what I need it for, and say plainly whether this report answers it.
3. If I want it, ask for my work email, my organization and the product: the current edition, or 3, 6 or 12 months of updates. Call create_order with report "NCT04277637", that product, email and organization, then show me the quote and the checkout_url to pay by card. If you have a wallet with a payment client for HTTP 402 (MPP with USDC on Tempo, or x402 with USDC on Base) and I agree, you can pay the pay_url instead. Nothing is charged until one is paid.
4. Once it is paid, call get_order with the status_url: it returns my license key. Then use the Erudio MCP server at https://mcp.erudio.com/mcp with the header "Authorization: Bearer <key>". Call read_report with report_id NCT04277637 and sections ["all"], and summarize the findings for me with their sources. The full report can be long: save the response to a file and work from it rather than printing it. If you cannot, read sections ["narratives"] first, the executive summary and analysis.
When you tell me what clinicians said, give each view as theirs, with its source. Counts are the sources the report kept, not the share of clinicians who agree. Reports are not medical advice.
Keep the key private to my organization.Or read the record directly: JSON, Markdown or MCP
curl https://www.erudio.com/reports/bgb-11417-101-nct04277637.json
curl https://www.erudio.com/reports/bgb-11417-101-nct04277637.md
# MCP, no sign-in (https://mcp.erudio.com/free)
get_report_card({ "slug": "bgb-11417-101-nct04277637" })release af919b7af379d3edb63faa112dd40a804e2eb49abf832564df5a6e5bb11a4e88
Questions
How much does the BGB-11417-101 report cost?
One edition costs $750 (Focused · 133 verified statements · 68 from 6 confirmed clinicians). With updates: 3 months $1,300, 6 months $1,900, 12 months $2,600. Subscriptions are prepaid, and the price is fixed for the term you buy, even if a new edition moves the trial up a size. Nothing renews automatically: a new term is bought at the price then current.
What does the BGB-11417-101 report cover?
133 statements from 27 sources (2 podcasts, 18 videos, 7 posts), 68 of them from 6 confirmed clinicians, each linked to its source. Commentary checked Nov 20, 2026. The report separates what clinicians said from what primary sources establish; it does not judge efficacy or estimate consensus.
Can my AI agent read or buy the BGB-11417-101 report?
Yes. On https://mcp.erudio.com/free, with no sign-in, get_report_card({ "slug": "bgb-11417-101-nct04277637" }) previews it and create_order({ "report": "bgb-11417-101-nct04277637", "product": "edition", "buyer_email": "<work email>" }) orders it. Once paid, the license key reads it with read_report on https://mcp.erudio.com/mcp. Connect your AI client.
How current is the BGB-11417-101 report?
Edition 1 (version 1.0.0), accepted Nov 20, 2026 UTC; last checked for new commentary Nov 20, 2026 UTC. Your plan includes every new edition published during its term. We automatically check subscribed trials for new commentary every week.